Table 4.
Metabolite | Basal (µmol) | 0–4 h (µmol) | 4–8 h (µmol) | 8–12 h (µmol) | 12–24 h (µmol) | Total (µmol) | |
---|---|---|---|---|---|---|---|
Intestinal Absorption | Epicatechin-3′-glucuronide | N.D. | 0.355 ± 0.071 | 0.267 ± 0.059 | <L.Q. | <L.Q. | 0.622 ± 0.130 * |
Epicatechin-3′-methoxy-glucuronide | N.D. | <L.Q. | <L.Q. | N.D. | N.D. | <L.Q. * | |
Epicatechin-3′-sulfate | N.D. | 1.323 ± 0.236 | 1.018 ± 0.178 | 0.076 ± 0.025 | <L.Q. | 2.417 ± 0.439 * | |
Epicatechin-methoxy-sulfate (isomer 1) | N.D. | 2.717 ± 0.457 | 1.300 ± 0.197 | 0.154 ± 0.031 | 0.257 ± 0.114 | 4.428 ± 0.800 * | |
Epicatechin-methoxy-sulfate (isomer 2) | N.D. | 0.181 ± 0.032 | 0.247 ± 0.030 | <L.Q. | <L.Q. | 0.428 ± 0.062 * | |
Epicatechin-methoxy-sulfate (isomer 3) | N.D. | 0.473 ± 0.089 | 0.285 ± 0.036 | <L.Q. | N.D. | 0.758 ± 0.125 * | |
Total—intestinal absorption | N.D. | 5.049 ± 0.885 | 3.117 ± 0.500 | 0.230 ± 0.056 | 0.257 ± 0.114 | 8.653 ± 1.556 * | |
Colonic Absorption | DHPVL | <L.Q. | <L.Q. | 0.146 ± 0.032 | <L.Q. | <L.Q. | 0.146 ± 0.032 * |
HPVL | N.D. | N.D. | <L.Q. | <L.Q. | <L.Q. | <L.Q. * | |
HDHPVA | N.D. | N.D. | <L.Q. | <L.Q. | <L.Q. | <L.Q. | |
HPVL-4′-glucuronide | <L.Q. | <L.Q. | 0.111 ± 0.049 | <L.Q. | <L.Q. | 0.111 ± 0.049 * | |
HPVL-3′-glucuronide | <L.Q. | <L.Q. | 0.497 ± 0.204 | 0.103 ± 0.028 | <L.Q. | 0.600 ± 0.232 * | |
HPVL-sulfate | 0.143 ± 0.064 | 0.456 ± 0.193 | 5.638 ± 1.922 | 1.945 ± 0.647 | 1.744 ± 0.374 | 9.926 ± 3.200 * | |
PVL-methoxy-glucuronide | <L.Q. | <L.Q. | 0.111 ± 0.039 | <L.Q. | <L.Q. | 0.111 ± 0.039 * | |
PVL-methoxy-sulfate | <L.Q. | N.D. | 0.085 ± 0.031 | <L.Q. | <L.Q. | 0.085 ± 0.031 * | |
PVL-3′glucuronide | N.D. | <L.Q. | 0.233 ± 0.155 | 0.126 ± 0.078 | 0.079 ± 0.022 | 0.438 ± 0.255 | |
PVL-3′-sulfate | <L.Q. | <L.Q. | 0.860 ± 0.385 | 0.456 ± 0.284 | 0.375 ± 0.133 | 1.691 ± 0.802 * | |
HHPVA-glucuronide | N.D. | N.D. | N.D. | N.D. | N.D. | N.D. * | |
HHPVA-sulfate | 0.089 ± 0.055 | 0.076 ± 0.055 | 1.112 ± 0.397 | 0.565 ± 0.171 | 0.503 ± 0.152 | 2.345 ± 0.830 * | |
Total—colonic absorption | 0.232 ± 0.119 | 0.532 ± 0.248 | 8.793 ± 3.214 | 3.195 ± 1.208 | 2.701 ± 0.681 | 15.453 ± 5.470 * | |
Other microbial metabolites | 3,4-Dihydroxyphenylpropionic acid | 0.117 ± 0.024 | 0.217 ± 0.051 | 0.243 ± 0.039 | 0.074 ± 0.017 | 0.215 ± 0.016 | 0.866 ± 0.148 |
3-Methoxy-4-hydroxyphenylpropionic acid | 0.104 ± 0.027 | 0.144 ± 0.044 | <L.Q. | <L.Q. | <L.Q. | 0.248 ± 0.071 | |
Hydroxyphenylpropionic acid | 0.118 ± 0.023 | 0.226 ± 0.046 | 0.259 ± 0.043 | 0.077 ± 0.018 | 0.203 ± 0.025 | 0.883 ± 0.154 | |
3,4-Dihydroxyphenylacetic acid | 0.094 ± 0.032 | 0.648 ± 0.505 | 0.556 ± 0.379 | 0.094 ± 0.033 | 0.133 ± 0.020 | 1.525 ± 0.974 | |
3-Methoxy-4-hydroxyphenylacetic acid | 0.103 ± 0.014 | 0.099 ± 0.054 | 0.093 ± 0.028 | <L.Q. | 0.103 ± 0.022 | 0.398 ± 0.118 | |
Hydroxyphenylacetic acid | 0.369 ± 0.077 | 0.408 ± 0.084 | 0.605 ± 0.092 | 0.225 ± 0.052 | 0.600 ± 0.100 | 2.208 ± 0.328 | |
Ferulic acid | <L.Q. | <L.Q. | 0.094 ± 0.009 | 0.099 ± 0.059 | N.D. | 0.193 ± 0.068 | |
Isoferulic acid | 0.170 ± 0.137 | 0.086 ± 0.028 | 0.096 ± 0.040 | 0.088 ± 0.069 | 0.082 ± 0.016 | 0.522 ± 0.290 | |
Protocatechuic acid | 0.161 ± 0.071 | 0.227 ± 0.142 | 0.373 ± 0.237 | 0.094 ± 0.047 | 0.104 ± 0.044 | 0.959 ± 0.217 * | |
Hydroxyhippuric acid | 0.821 ± 0.251 | 0.864 ± 0.154 | 1.171 ± 0.387 | 0.242 ± 0.067 | 0.995 ± 0.316 | 4.093 ± 1.175 | |
Hydroxyhippuric acid | 0.075 ± 0.031 | 0.085 ± 0.043 | 0.082 ± 0.055 | 0.075 ± 0.031 | 0.077 ± 0.046 | 0.394 ± 0.206 | |
Hidroxybenzoic acid | 0.188 ± 0.041 | 0.145 ± 0.027 | 0.200 ± 0.051 | 0.070 ± 0.018 | 0.195 ± 0.025 | 0.798 ± 0.162 | |
Total other microbial metabolites | 2.320 ± 0.728 | 3.149 ± 1.178 | 3.772 ± 1.360 | 1.138 ± 0.411 | 2.707 ± 0.630 | 13.086 ± 3.911 | |
INTESTINAL + COLONIC METABOLITES | 0.232 ± 0.119 | 5.581 ± 1.133 | 11.910 ± 3.714 | 3.425 ± 1.264 | 2.958 ± 0.795 | 24.106 ± 7.026 |
HDHPVA: 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid; DHPVL: 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone; HPVL: 5-(3′-hydroxyphenyl)-γ-valerolactone; PVL: 5-phenyl-γ-valerolactone. * Significant differences respect to CC-PP intervention was observed based on non-parametric Wilcoxon test at p < 0.05. Values represent mean ± standard deviation (n = 13). N.D.: not detected; <L.Q. lower than quantification limit.